HepG2: A Human Liver Cancer Cell Line for Metabolism and Toxicology Studies
HepG2 is a well-characterized human hepatocellular carcinoma (HCC) cell line established from the liver tumor of a 15-year-old Caucasian male. The cells grow as adherent monolayers and exhibit epithelial morphology. Importantly, HepG2 retains many differentiated hepatic functions, including the synthesis of key plasma proteins such as albumin, transferrin, and fibrinogen. It also expresses several drug-metabolizing enzymes, including phase I and phase II enzymes, though cytochrome P450 activity is limited compared to primary hepatocytes.
Due to its hepatic origin and functional stability, HepG2 is extensively used in drug metabolism, toxicology, and pharmacokinetics research. It serves as a platform for evaluating hepatotoxic responses, studying gene expression regulation, and conducting high-throughput screening for pharmaceutical compounds. Its high compatibility with transfection techniques and reproducibility in culture make HepG2 a cornerstone in in vitro liver studies and early-stage drug development.
Hep-3B: A p53-Deficient HCC Model with Integrated HBV DNA
Hep-3B is a human hepatocellular carcinoma cell line derived from the liver tumor of an 8-year-old African-American male. It is genetically distinct from other hepatic models due to two key features: a complete deletion of the TP53 gene and the presence of integrated hepatitis B virus (HBV) DNA. These characteristics make Hep-3B highly relevant for investigating virus-driven oncogenesis and the role of p53 loss in liver cancer progression.
The cell line produces liver-specific proteins such as albumin and alpha-fetoprotein (AFP), and exhibits moderate hepatic metabolic activity. Hep-3B is frequently used to study hepatocarcinogenesis, HBV replication, RNA interference, and tumor suppressor signaling. It is amenable to both siRNA and plasmid transfection, making it a useful system for gene modulation and therapeutic target validation. Its p53-deficient status also enables exploration of DNA damage response pathways and drug sensitivity in a genetically defined tumor background.
HUH-7: A Hepatoma Cell Line for Liver Cancer and Virology Research
The HUH-7 cell line was derived from a well-differentiated hepatocellular carcinoma in a 57-year-old Japanese male. It is among the most widely used hepatic models in biomedical research due to its epithelial morphology, stable proliferation, and retention of several hepatocyte functions, including the expression of albumin, alpha-fetoprotein, and various transporters and metabolic enzymes.
HUH-7 is particularly important in virology research, as it is highly permissive to hepatitis C virus (HCV) and hepatitis B virus (HBV) replication. Its subclone, HUH-7.5, is even more effective in HCV studies due to a RIG-I pathway defect that enhances viral replication. Beyond virology, HUH-7 is also widely used in cancer research, drug screening, and gene function studies. The cell line responds well to genetic manipulation using plasmids, siRNA, and CRISPR/Cas9 technologies. HUH-7 xenografts can be established in immunodeficient mice, making this model suitable for in vivo tumor studies and preclinical drug testing.
Hepa 1-6: A Murine Hepatoma Cell Line for Immunocompetent Liver Cancer Models
Hepa 1-6 is a murine hepatoma cell line derived from a BW7756 liver tumor in a male C57L mouse. It exhibits hepatocyte-like morphology and expresses several liver-specific markers, including albumin and alpha-fetoprotein. Although it does not fully replicate the enzymatic complexity of human hepatocytes, Hepa 1-6 is an invaluable model in mouse-based cancer research due to its compatibility with syngeneic transplantation in immunocompetent hosts.
This cell line is widely used in immuno-oncology, tumor microenvironment, and in vivo liver cancer studies. Because it can be transplanted into C57L or C57BL/6 mice without triggering immune rejection, Hepa 1-6 enables preclinical evaluation of immune-based therapies, checkpoint inhibitors, and vaccine candidates in a fully functional immune system. Additionally, the line is compatible with gene knockdown and overexpression techniques, supporting gene function and target validation studies in mouse models of liver cancer.
